These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9650562)

  • 21. Inhibition of endothelial cell movement and tubulogenesis by human recombinant soluble melanotransferrin: involvement of the u-PAR/LRP plasminolytic system.
    Michaud-Levesque J; Rolland Y; Demeule M; Bertrand Y; Béliveau R
    Biochim Biophys Acta; 2005 Apr; 1743(3):243-53. PubMed ID: 15843038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo.
    Zhou H; Tang Y; Liang X; Yang X; Yang J; Zhu G; Zheng M; Zhang C
    Int J Cancer; 2009 Jul; 125(2):453-62. PubMed ID: 19391133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.
    Guiducci S; Del Rosso A; Cinelli M; Perfetto F; Livi R; Rossi A; Gabrielli A; Giacomelli R; Iori N; Fibbi G; Del Rosso M; Cerinic MM
    Arthritis Res Ther; 2005; 7(6):R1244-53. PubMed ID: 16277677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
    Tavian D; Salvi A; De Petro G; Barlati S
    Cancer Gene Ther; 2003 Feb; 10(2):112-20. PubMed ID: 12536199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell cycle-dependent fluctuation of urokinase-type plasminogen activator, its receptor, and inhibitors in cultured bovine mammary epithelial and myoepithelial cells.
    Zavizion B; White JH; Bramley AJ
    Biochim Biophys Acta; 1998 Jun; 1403(2):141-50. PubMed ID: 9630579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of urokinase-type plasminogen activator in human gastric cancer cell line (AGS) induces tumorigenicity in severe combined immunodeficient mice.
    Choi YK; Yoon BI; Kook YH; Won YS; Kim JH; Lee CH; Hyun BH; Oh GT; Sipley J; Kim DY
    Jpn J Cancer Res; 2002 Feb; 93(2):151-6. PubMed ID: 11856478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-1beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells.
    Chung HW; Wen Y; Ahn JJ; Moon HS; Polan ML
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1332-40. PubMed ID: 11238529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo and in vitro expression of the plasminogen activators and urokinase type plasminogen activator receptor (u-PAR) in the pig oviduct.
    Roldán-Olarte M; García DC; Jiménez-Díaz M; Valdecantos PA; Miceli DC
    Anim Reprod Sci; 2012 Dec; 136(1-2):90-9. PubMed ID: 23103014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
    Clayman G; Wang SW; Nicolson GL; el-Naggar A; Mazar A; Henkin J; Blasi F; Goepfert H; Boyd DD
    Int J Cancer; 1993 Apr; 54(1):73-80. PubMed ID: 8386710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of metastasis by inhibition of the urokinase receptor.
    Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein.
    Margheri F; D'Alessio S; Serratì S; Pucci M; Del Rosso A; Benelli R; Ferrari N; Noonan DM; Albini A; Fibbi G; Del Rosso M
    Int J Oncol; 2005 Jul; 27(1):223-35. PubMed ID: 15942664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
    Leupold JH; Asangani I; Maurer GD; Lengyel E; Post S; Allgayer H
    Mol Cancer Res; 2007 May; 5(5):485-96. PubMed ID: 17510314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice.
    Carmeliet P; Moons L; Dewerchin M; Rosenberg S; Herbert JM; Lupu F; Collen D
    J Cell Biol; 1998 Jan; 140(1):233-45. PubMed ID: 9425170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
    Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
    Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
    Boyd DD; Wang H; Avila H; Parikh NU; Kessler H; Magdolen V; Gallick GE
    Clin Cancer Res; 2004 Feb; 10(4):1545-55. PubMed ID: 14977859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
    Lijnen HR; De Cock F; Collen D
    Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade.
    Lengyel E; Wang H; Gum R; Simon C; Wang Y; Boyd D
    Oncogene; 1997 May; 14(21):2563-73. PubMed ID: 9191056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor.
    Anichini E; Fibbi G; Pucci M; Caldini R; Chevanne M; Del Rosso M
    Exp Cell Res; 1994 Aug; 213(2):438-48. PubMed ID: 8050501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
    Ueshima S; Fukao H; Okada K; Matsuo O
    Thromb Res; 2004; 113(1):41-9. PubMed ID: 15081564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.